World Premier International Research Center Initiative (WPI) Executive Summary (For Extension Application Screening)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Blueprint for Engineering Cell Fate: Current Technologies to Reprogram Cell Identity
Cell Research (2013) 23:33-48. © 2013 IBCB, SIBS, CAS All rights reserved 1001-0602/13 $ 32.00 npg REVIEW www.nature.com/cr A blueprint for engineering cell fate: current technologies to reprogram cell identity Samantha A Morris1, 2, 3, George Q Daley1, 2, 3 1Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Manton Center for Orphan Disease Re- search, Howard Hughes Medical Institute, Children’s Hospital Boston and Dana Farber Cancer Institute, Boston, MA, USA; 2De- partment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; 3Harvard Stem Cell Institute, Cambridge, MA, USA Human diseases such as heart failure, diabetes, neurodegenerative disorders, and many others result from the deficiency or dysfunction of critical cell types. Strategies for therapeutic tissue repair or regeneration require the in vitro manufacture of clinically relevant quantities of defined cell types. In addition to transplantation therapy, the generation of otherwise inaccessible cells also permits disease modeling, toxicology testing and drug discovery in vitro. In this review, we discuss current strategies to manipulate the identity of abundant and accessible cells by dif- ferentiation from an induced pluripotent state or direct conversion between differentiated states. We contrast these approaches with recent advances employing partial reprogramming to facilitate lineage switching, and discuss the mechanisms underlying the engineering of cell fate. Finally, we address the current limitations of the field and how the resulting cell types can be assessed to ensure the production of medically relevant populations. Keywords: reprogramming; direct fate conversion; directed differentiation Cell Research (2013) 23:33-48. doi:10.1038/cr.2013.1; published online 1 January 2013 Introduction could only transition to progressively more differentiated states, with de-differentiation seen only in cases of tissue Cell differentiation has long been thought to be a uni- pathology (e.g., metaplasia or malignancy). -
Project Final Report
PROJECT FINAL REPORT Grant Agreement number: 229289 Project acronym: NANOII Project title: Nanoscopically-guided induction and expansion of regulatory hematopoietic cells to treat autoimmune and inflammatory processes Funding Scheme: Period covered: from month 1 to month 48 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Dr. Joachim P. Spatz, Max-Planck-Institute, Stuttgart Tel: +49 711 689-3611 Fax: +49 711 689-3612 E-mail: [email protected] Project website address: http://www.mf.mpg.de/NanoII 1 4.1 Final publishable summary report Executive Summary NanoII Nanoscopically-guided induction and expansion of regulatory hematopoietic cells to treat autoimmune and inflammatory processes NanoII has been a colaborative project within the EU 7th framework program for research on Nanoscopically-guided induction and expansion of regulatory hematopoietic cells to treat autoimmune and inflammatory processes. This project has been developing novel approaches for directing the differentiaton, proliferation and tissue tropism of specific hematopoietic lineages, using micro-and nanofabricated cell chips. We are using advanced nanofabricated surfaces functionalized with specific biomolecules, and microfluidic cell chips to specify and expand regulatory immune cell for treating of important inflammatory and autoimmune disorders in an organ and antigen-specific manner. A new chip system creates ex vivo microenvironments mimicking in vivo cell-cell-interactions and molecular signals involved in differentiation and proliferation of hematopoietic cells. Key element of the project is the development of a novel high-throughput microscopy system for the identification of optimal conditions. The educated cells are employed in in-vivo experiments in new mouse models. -
Directed Differentiation of Human Embryonic Stem Cells
DirectedDirected differentiationdifferentiation ofof humanhuman embryonicembryonic stemstem cellscells TECAN Symposium 2008 Biologics - From Benchtop to Production Wednesday 17 September 2008 Andrew Elefanty Embryonic Stem Cell Differentiation Laboratory, MISCL ES cells as a system to dissect development hES ES cells derived from inner cell mass of preimplantation blastocyst Functionally similar, patient specific cells generated by reprogramming adult or fetal cells: • Somatic cell nuclear transfer (SCNT) - oocyte cytoplasm reprograms somatic cell • Induced pluripotential stem cell (iPS) – reprogramming is initiated by genes and/or growth factors introduced into adult cells ES cells can differentiate into all the cell types in the body blood cells differentiation liver heart muscle pancreas ES cell line nerve In vitro differentiation of embryonic stem cells provides an avenue to • study early development • generate tissue specific stem cells and mature end cells to study disease to screen drugs/therapeutic agents for cell therapies Directed differentiation of ES cells Recapitulate embryonic development in vitro to derive lineage precursors hES Mesendoderm Ectoderm Mesoderm Endoderm Factors that play key roles in embryogenesis also direct differentiation of ES cells hES BMP/Activin/Wnt/FGF Mesendoderm FGF/noggin BMP/Wnt Activin Ectoderm Mesoderm Endoderm Elements that facilitate directed differentiation of HESCs in vitro •large, uniform populations of undifferentiated HESCs •robust, reproducible differentiation protocol incorporating a -
Health Services Research (Including System Process Change)
April 2013 Roadmap to the Research Hospital of the Future 1 Table of Contents INTRODUCTION ............................................................................................................. 3 KEY ASSUMPTIONS ...................................................................................................... 5 THEMES AND DEFINITIONS ......................................................................................... 6 TRENDS SUMMARY ...................................................................................................... 8 REGENERATIVE MEDICINE ........................................................................................ 11 EXPERIMENTAL THERAPEUTICS…………………..……………………………….…….19 MEDICAL TECHNOLOGY ............................................................................................ 29 INFORMATICS AND PATIENT INFORMATION COLLECTION & ASSESSMENT ...... 46 HEALTH SERVICES RESEARCH (INCLUDING SYSTEM PROCESS CHANGE) ....... 55 MECHANISMS OF DISEASE ....................................................................................... 73 RESEARCH AND EDUCATION ................................................................................... 89 APPENDIX .................................................................................................................... 94 GLOSSARY OF TERMS & ABBREVIATIONS ............................................................. 95 2 Introduction The UHN Research community undertook a major strategic planning exercise in 2002 in response to the release of the -
Nano-Biosensor for Monitoring the Neural Differentiation of Stem Cells
nanomaterials Review Nano-Biosensor for Monitoring the Neural Differentiation of Stem Cells Jin-Ho Lee 1,2,†, Taek Lee 1,2,† and Jeong-Woo Choi 1,2,* 1 Department of Chemical and Biomolecular Engineering, Sogang University, 35 Baekbeom-ro (Sinsu-dong), Mapo-gu, Seoul 121-742, Korea; [email protected] (J.-H.L.); [email protected] (T.L.) 2 Institute of Integrated Biotechnology, Sogang University, 35 Baekbeom-ro (Sinsu-dong), Mapo-gu, Seoul 121-742, Korea * Correspondence: [email protected]; Tel.: +82-2-718-1976; Fax: +82-2-3273-0331 † These authors contributed equally to this work. Academic Editors: Chen-Zhong Li and Ling-Jie Meng Received: 6 July 2016; Accepted: 17 November 2016; Published: 28 November 2016 Abstract: In tissue engineering and regenerative medicine, monitoring the status of stem cell differentiation is crucial to verify therapeutic efficacy and optimize treatment procedures. However, traditional methods, such as cell staining and sorting, are labor-intensive and may damage the cells. Therefore, the development of noninvasive methods to monitor the differentiation status in situ is highly desirable and can be of great benefit to stem cell-based therapies. Toward this end, nanotechnology has been applied to develop highly-sensitive biosensors to noninvasively monitor the neural differentiation of stem cells. Herein, this article reviews the development of noninvasive nano-biosensor systems to monitor the neural differentiation of stem cells, mainly focusing on optical (plasmonic) and eletrochemical methods. The findings in this review suggest that novel nano-biosensors capable of monitoring stem cell differentiation are a promising type of technology that can accelerate the development of stem cell therapies, including regenerative medicine. -
Cyclodextrin-Based Rotaxanes for Material Science Applications
Cyclodextrin-Based Rotaxanes for Material Science Applications A thesis submitted for admission to the degree of Doctor of Philosophy By Hwi Young Lee Australian INcUIUMcll University Research School of Chemistry Canberra, Australia April, 2014 Author’s Statement This is to declare that the work in this thesis represents original work that I have undertaken during my PhD degree at the Research School of Chemistry, the Australian National University from 2010 to 2014, except the synthesis and X-ray crystal analysis of the compounds 4.1 and 4.2, and the synthesis of compounds 4.4 and 4.5, which was carried out as part of my PhB Honours degree. To my best of knowledge, the thesis does not contain material that has been published or written by another person or accepted for the award of any other degree of diploma in any other university or tertiary institution, unless due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University library, being available for loan or photocopying. April 2014 l Acknowledgements I would like to express my most sincere gratitude to my supervisor, Prof. Christopher J. Easton. This work would not have been possible without his guidance, patience and understanding. I appreciate the time and energy you put into students' academic excellence and personal welfare. I am also grateful that you have never stopped providing me with challenges and inspiration. I am extremely grateful to Dr Hideki Onagi for introducing me to cyclodextrin chemistry. I appreciate your willingness to sacrifice your lunch breaks, late evenings and even weekends to share your expertise. -
Biomimetic Coatings Obtained by Combinatorial Laser Technologies
coatings Review Biomimetic Coatings Obtained by Combinatorial Laser Technologies Emanuel Axente 1 , Livia Elena Sima 2 and Felix Sima 1,* 1 Center for Advanced Laser Technologies (CETAL), National Institute for Laser, Plasma and Radiation Physics (INFLPR), 409 Atomistilor, Magurele 077125, Romania; emanuel.axente@inflpr.ro 2 Department of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy, 296 Splaiul Independentei, Bucharest 060031, Romania; [email protected] * Correspondence: felix.sima@inflpr.ro; Tel.: +4-021-457-4243 Received: 13 April 2020; Accepted: 7 May 2020; Published: 9 May 2020 Abstract: The modification of implant devices with biocompatible coatings has become necessary as a consequence of premature loosening of prosthesis. This is caused mainly by chronic inflammation or allergies that are triggered by implant wear, production of abrasion particles, and/or release of metallic ions from the implantable device surface. Specific to the implant tissue destination, it could require coatings with specific features in order to provide optimal osseointegration. Pulsed laser deposition (PLD) became a well-known physical vapor deposition technology that has been successfully applied to a large variety of biocompatible inorganic coatings for biomedical prosthetic applications. Matrix assisted pulsed laser evaporation (MAPLE) is a PLD-derived technology used for depositions of thin organic material coatings. In an attempt to surpass solvent related difficulties, when different solvents are used for blending various organic materials, combinatorial MAPLE was proposed to grow thin hybrid coatings, assembled in a gradient of composition. We review herein the evolution of the laser technological process and capabilities of growing thin bio-coatings with emphasis on blended or multilayered biomimetic combinations. -
Bilkent-Graduate Catalog 0.Pdf
ISBN: 978-605-9788-11-3 bilkent.edu.tr ACADEMIC OFFICERS OF THE UNIVERSITY Ali Doğramacı, Chairman of the Board of Trustees and President of the University CENTRAL ADMINISTRATION DEANS OF FACULTIES Abdullah Atalar, Rector (Chancellor) Ayhan Altıntaş, Faculty of Art, Design, and Architecture (Acting) Adnan Akay, Vice Rector - Provost Mehmet Baray, Faculty of Education (Acting) Kürşat Aydoğan, Vice Rector Ülkü Gürler, Faculty of Business Administration (Acting) Orhan Aytür, Vice Rector Ezhan Karaşan, Faculty of Engineering Cevdet Aykanat, Associate Provost Hitay Özbay, Faculty of Humanities and Letters (Acting) Hitay Özbay, Associate Provost Tayfun Özçelik, Faculty of Science Özgür Ulusoy Associate Provost Turgut Tan, Faculty of Law Erinç Yeldan, Faculty of Economics, Administrative, and Social Sciences (Acting) GRADUATE SCHOOL DIRECTORS Alipaşa Ayas, Graduate School of Education [email protected] Halime Demirkan, Graduate School of Economics and Social Sciences [email protected] Ezhan Karaşan, Graduate School of Engineering and Science [email protected] DEPARTMENT CHAIRS and PROGRAM DIRECTORS Michelle Adams, Neuroscience [email protected] Adnan Akay, Mechanical Engineering [email protected] M. Selim Aktürk, Industrial Engineering [email protected] Orhan Arıkan, Electrical and Electronics Engineering [email protected] Fatihcan Atay, Mathematics [email protected] Pınar Bilgin, Political Science and Public Administration [email protected] Hilmi Volkan Demir, Materials Science and Nanotechnology [email protected] Oğuz Gülseren, Physics [email protected] Ahmet Gürata, Communication and Design [email protected] Meltem Gürel, Architecture [email protected] Refet Gürkaynak, Economics [email protected] Ülkü Gürler, Business Administration (Acting) [email protected] H. -
Sex-Dependent VEGF Expression Underlies Variations in Human Pluripotent Stem Cell to Endothelial Progenitor Differentiation
www.nature.com/scientificreports OPEN Sex-dependent VEGF expression underlies variations in human pluripotent stem cell to endothelial progenitor diferentiation Lauren N. Randolph1,2, Xiaoping Bao4, Michael Oddo1 & Xiaojun Lance Lian1,2,3* Human pluripotent stem cells (hPSCs) ofer tremendous promise in tissue engineering and cell-based therapies because of their unique combination of two properties: pluripotency and a high proliferative capacity. To realize this potential, development of efcient hPSC diferentiation protocols is required. In this work, sex-based diferences are identifed in a GSK3 inhibitor based endothelial progenitor diferentiation protocol. While male hPSCs efciently diferentiate into CD34 + CD31+ endothelial progenitors upon GSK3 inhibition, female hPSCs showed limited diferentiation capacity using this protocol. Using VE-cadherin-GFP knockin reporter cells, female cells showed signifcantly increased diferentiation efciency when treated with VEGF during the second stage of endothelial progenitor diferentiation. Interestingly, male cells showed no signifcant change in diferentiation efciency with VEGF treatment, but did show augmented early activation of VE-cadherin expression. A sex-based diference in endogenous expression of VEGF was identifed that is likely the underlying cause of discrepancies in sex-dependent diferentiation efciency. These fndings highlight the importance of sex diferences in progenitor biology and the development of new stem cell diferentiation protocols. In the regenerative medicine feld, topics such as personalized medicine, immunoengineering, and stem cell ther- apies are frequently discussed; however, cell sex variations are rarely considered despite prevalent evidence of sex diferences in many diferent diseases, such as cardiovascular disease, autoimmune disease, Alzheimer disease, and diabetes1–6. Many of these conditions involve malfunction or attack of terminally diferentiated senescent cells making them excellent candidates for the development of stem cell-based therapies. -
Reproducible Cells and Organoids Via Directed-Differentiation Encoding (RECODE)
This document has been archived and replaced by NSF 21-532. Reproducible Cells and Organoids via Directed-Differentiation Encoding (RECODE) PROGRAM SOLICITATION NSF 20-541 National Science Foundation Directorate for Engineering Division of Chemical, Bioengineering, Environmental and Transport Systems Letter of Intent Due Date(s) (required) (due by 5 p.m. submitter's local time): March 02, 2020 Full Proposal Deadline(s) (due by 5 p.m. submitter's local time): May 14, 2020 IMPORTANT INFORMATION AND REVISION NOTES Any proposal submitted in response to this solicitation should be submitted in accordance with the revised NSF Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 20-1), which is effective for proposals submitted, or due, on or after June 1, 2020. SUMMARY OF PROGRAM REQUIREMENTS General Information Program Title: Reproducible Cells and Organoids via Directed- Differentiation Encoding (RECODE) Synopsis of Program: The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET), seeks proposals that elucidate mechanisms of, and develop strategies to, direct the differentiation of undifferentiated cells into mature, functional cells or organoids. Projects responsive to this solicitation must aim to establish a robust and reproducible set of differentiation design rules, predictive models, real-time sensing, control, and quality assurance methods, and integrate them into a workable differentiation strategy. They must develop a fundamental understanding of how cells develop, including mechanisms, molecular machinery, dynamics, and cell-cell interactions, and use this understanding to manipulate cells purposefully. Investigators can choose any undifferentiated cell type, from any animal species, as a starting point and choose any appropriate functional product (cell, organoid, etc.) with real-world relevance. -
Meeting the Need for Regenerative Therapies I
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2012 Meeting the need for regenerative therapies I: Target-based incidence and its relationship to U.S spending, productivity, and innovation Nancy Parenteau Parenteau BioConsultants Janet Hardin-Young Parenteau BioConsultants William Shannon Washington University School of Medicine in St. Louis Patrick Cantini The McGowan Institute of Regenerative Medicine Alan Russell University of Pittsburgh - Main Campus Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Parenteau, Nancy; Hardin-Young, Janet; Shannon, William; Cantini, Patrick; and Russell, Alan, ,"Meeting the need for regenerative therapies I: Target-based incidence and its relationship to U.S spending, productivity, and innovation." Tissue Engineering: Part B.18,2. 139-154. (2012). https://digitalcommons.wustl.edu/open_access_pubs/3281 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. TISSUE ENGINEERING: Part B Volume 18, Number 2, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/ten.teb.2011.0454 Meeting the Need for Regenerative Therapies I: Target-Based Incidence and Its Relationship to U.S. Spending, Productivity, and Innovation Nancy Parenteau, Ph.D.,1 Janet Hardin-Young, Ph.D.,1 William Shannon, Ph.D.,2,3 Patrick Cantini, B.A.,4 and Alan Russell, Ph.D.4,5 Regenerative therapies possess high theoretical potential for medical advance yet their success as commercial therapeutics is still open to debate. Appropriate data on target opportunities that provide perspective and enable strategic decision making is necessary for both efficient and effective translation. -
Directed Differentiation of Human Pluripotent Stem Cells Into Radial Glia and Astrocytes
bioRxiv preprint doi: https://doi.org/10.1101/2021.08.23.457423; this version posted August 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Directed Differentiation of Human Pluripotent Stem Cells into Radial Glia and Astrocytes Bypasses Neurogenesis Vukasin M. Jovanovic1, Claire Malley1, Carlos A. Tristan1, Seungmi Ryu1, Pei-Hsuan Chu1, Elena Barnaeva1, Pinar Ormanoglu1, Jennifer Colon Mercado2, Sam Michael1, Michael E. Ward2, Anton Simeonov1, Ilyas Singeç1* 1National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation, Stem Cell Translation Laboratory (SCTL), Rockville, MD 20850, USA 2National Institute of Neurological Disorders and Stroke (NINDS), Inherited Neurodegenerative Disease Unit, Bethesda, MD 20892, USA National Institutes of Health (NIH) *Correspondence: [email protected] Dr. Ilyas Singeç Stem Cell Translation Laboratory (SCTL) NIH Regenerative Medicine Program NIH National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive Rockville, MD 20850, USA 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.08.23.457423; this version posted August 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Abstract Derivation of astrocytes from human pluripotent stem cells (hPSCs) is inefficient and cumbersome, impeding their use in biomedical research.